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194Objective: Prophylactic retrosternal placement of a gentamicin-collagen sponge has been the subject of several
recent clinical studies and is a matter of controversy. The present study is the first controlled, prospective, ran-
domized, double-blind, single-center study to investigate the efficacy of a retrosternal gentamicin-collagen
sponge in reducing sternal wound complications after heart surgery.
Methods: From June 2009 to June 2010, 720 consecutive patients who underwent median sternotomy were as-
signed to a control placebo group (collagen sponge) or an intervention group (gentamicin-collagen sponge). All
patients received guideline-compliant perioperative antibiotic prophylaxis. The primary end point was the oc-
currence of deep sternal wound infections within 30 days of index surgery (follow-up period). Secondary end
points were the occurrence of superficial sternal wound infections requiring treatment, as well as further clinical
parameters, including revision, bleeding volume, and need for transfusions during the follow-up period.
Results: A total of 720 of 994 patients (72.4%) were enrolled (control group: n ¼ 367 vs intervention group:
n¼ 353). Risk factors for sternal wound infection and demographic variables were comparable in the 2 groups.
The incidence of deep sternal wound infections was 13 of 367 (3.52%) in the control group versus 2 of 353
(0.56%) in the intervention group (P ¼ .014; adjusted odds ratio, 0.15; 95% confidence interval, 0.02–0.69).
The numbers needed to treat relation for all sternal wound infections and deep sternal wound infections were
26 and 33, respectively. No statistically significant differences were demonstrated concerning secondary end
points, such as postoperative bleeding and transfusion of red cell units, thrombocytes, and fresh-frozen plasma.
Conclusions: Routine prophylactic retrosternal use of a gentamicin-collagen sponge in patients undergoing car-
diac surgery significantly reduces deep sternal wound infections. (J Thorac Cardiovasc Surg 2012;143:194-200)Median sternotomy is the method of first choice in most
cardiac surgical interventions. Postoperative sternal
wound infections are reported to occur with an incidence
of approximately 0.5% to 8%.1 However, particularly in
the case of deep sternal wound infections (DSWIs) they
are associated with high mortality rates of 14% to
47%.2 The causes of DSWI are multifactorial. Risk fac-
tors include patient-related factors (endogenous) and
those due to the surgical intervention and hospital stay
(exogenous). A number of prospective and retrospective
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The Journal of Thoracic and Cardiovascular Surgbecause they are targets for preventive measures.2-8 The
basic requirements for uncomplicated wound healing
are aseptic surgery, perfect osteosynthesis, and optimal
antimicrobial prophylaxis. Local antibiotic-eluting
products are already being used in the treatment of oste-
omyelitis, soft-tissue infections, and mediastinitis.9-12
The effectiveness of the routine retrosternal placement
of a gentamicin-collagen sponge before suture closure
is currently a matter of some controversy.13-16 Local
use results in initially high local concentrations at
the implantation site without causing toxic serum
levels. This counters the risk of resistance development
while at the same time avoiding systemic adverse
effects of the aminoglycoside, for example, ototoxicity
and nephrotoxicity.9,12,17-19 However, the carrier is
a foreign body that should be removed promptly once
the active substance has been largely eluted or made of
fully biodegradable material to prevent persistence of
an infective focus. Thus, a collagen matrix seems to be
suitable in situations in which removal is not a viable
option, such as sternotomy. The present study is the
first controlled, prospectively randomized, double-blind,
single-center study to investigate the efficacy of a genta-
micin-collagen sponge in reducing sternal woundery c January 2012
Abbreviations and Acronyms
DSWI ¼ deep sternal wound infection
SSWI ¼ superficial sternal wound infection
Schimmer et al Perioperative Managementcomplications after heart surgery and meets the criteria
of evidence grade 1b.MATERIALS AND METHODS
In the period between June 15, 2009, and June 30, 2010, 994 operations
were performed on the heart and thoracic aorta via median sternotomy at
the Clinic for Thoracic, Cardiac and Thoracic Vascular Surgery of
W€urzburg University Hospital. A total of 800 of 994 patients (80.5%)
met the inclusion criteria, which were defined as follows: male and female
legally competent patients, elective and emergency, age 18 years or older,
cardiac surgery undergoing first or resternotomy, ability to provide written
informed consent, and no preoperative signs of thoracic inflammation. Ex-
clusion criteria were defined as follows: existing osteitis, immunosuppres-
sive therapy, known hypersensitivity to aminoglycoside antibiotics,
concurrent immunologic disease, pregnancy or lactation, participation in
another clinical study, inability to give consent to participate in the study,
and refusal to participate in the study before or during the follow-up period
(Figure 1).
For the study, 400 pure collagen sponges (203 53 0.5 cm; 1 cm2 con-
taining 2.8 mg native collagen fibrils of equine origin; placebo) and 400
identical gentamicin-collagen sponges (also containing 2 mg gentamicin
sulphate, equivalent to 1.10–1.43 mg gentamicin; verum) were used. The
2 sponges looked identical and could not be differentiated by the surgeon
on the basis of their appearance or haptic characteristics. The study sponges
(verumþplacebo) were provided free of charge by RESORBAWundver-
sorgung GmbH & Co KG, 90475 N€urnberg. An agreement on the cooper-
ation was drawn up with the Legal Department of W€urzburg University
Hospital. Financial remuneration and the possibility of influencing the pub-
lication of the findings were ruled out by the agreement. None of the parties
involved received any remuneration from RESORBA Wundversorgung
GmbH & Co KG before, at the time of the study, or at the time of publica-
tion of the findings. The corresponding author had full access to all data and
final responsibility for the decision to submit for publication. All criteriaCardiosurgical patients 
with median sternotomy 
during the observation 
period (n = 994) 
Patients enrolled and 
randomised 
(n = 800)
Complete follow-up 
(n = 720)
Intervention 
group
n = 353 
Placebo 
group 
n = 367 
80 excluded:
40 revision surgery of bleeding 
20 perioperative mortality 
20 non-use of  the specified 
sponge 
194 not enrolled:
17 exclusion criteria 
177 refusal to consent 
FIGURE 1. Trial profile.
The Journal of Thoracic and Cademanded of a randomized, double-blind study were met at all times, so
that the study meets the criteria of the Oxford Centre for Evidence-based
Medicine for evidence grade 1b. Randomization and blinding were carried
out by the Centre for Clinical Studies ofW€urzburg University Hospital. Af-
ter randomization, the 400 gentamicin-collagen sponges and the 400 pla-
cebo sponges were labeled with a sticker showing the randomization
number. Once all the sponges were used, the data were unblinded and an-
alyzed by the Institute of Mathematics and Informatics, Chair for Statistics
of W€urzburg University. The study was approved by the Ethics Committee
of W€urzburg University Hospital (reference No. 69/09). This trial is regis-
tered at Current Controlled Trials Limited, London with the assign
ISRCTN 20849.Primary and Secondary End Points
All patients were examined once daily up to the time of discharge for
wound healing and signs of infection. Preoperatively and on postoperative
days 1, 2, 4, and 7 and on the day before discharge, the leucocyte count,
C-reactive protein, and thrombocyte count were determined. If infection
was suspected, these parameters were also measured on an ad hoc basis.
To detect further infections after discharge, patients were instructed to re-
port any signs of infection and they were contacted by phone 30 days post-
operatively. The primary end point of the study was the occurrence of
a DSWI/mediastinitis within the 30-day follow-up period after index sur-
gery. Secondary end points were the occurrence of a superficial sternal
wound infection (SSWI) requiring treatment and the following parameters:
revision, total bleeding volume, and need for transfusion during the follow-
up period. DSWI and SSWI were defined on the basis of the criteria of the
US Centers for Disease Control and Prevention as a positive bacterial cul-
ture from mediastinal tissue or fluid, and an intraoperative clinical picture
of mediastinitis in the presence of one of the following: chest pain, sternal
instability, fever greater than 38C, purulent secretion from the mediasti-
num, or positive bacterial culture from the blood or mediastinal drainage
fluid. An SSWI was deemed present if there was microbiological evidence
of microbes in the cutaneous or subcutaneous tissue at the site of the inci-
sion, the incision was purposely reopened, or at least one of the following
secondary diagnoses was made: purulent secretion from the superficial in-
cision with or without laboratory confirmation, positive bacterial culture
from a fluid or tissue sample taken from the superficial incision under asep-
tic conditions, and at least 1 sign/symptom of infection: redness, heat, pain,
or swelling.20P
MSurgical Procedure
After complete adaptation of the pericardium and preliminary place-
ment of the sternal wiring, the study sponge was implanted retrosternally
without premoistening (Figure 2).
Sternal wiring was then performed. The closure techniques used were
trans-/peristernal, figure of 8, or band cerclages. The wound was then
closed in layers by sutures and covered with a sterile dressing. Each patient
routinely received guideline-compliant perioperative prophylaxis with in-
travenous cefuroxime (1.5 g twice per day) starting 30 minutes before
the operation for up to 48 hours postoperatively. The preoperative, intrao-
perative, and postoperative protocol for preventing wound infections was
not changed during the course of the study. There were no changes in the
hygiene or surgical procedure during that time.Statistical Analysis
Statistical analysis was performed by an independent statistician at the
Institute of Mathematics and Informatics, Chair of Mathematics VIII (Sta-
tistics), University of W€urzburg. The open source software R (version
2.12.1) was used. For ratio-scaled variables, a descriptive overview of
the 2 groups (active drug vs placebo) was always prepared. The 2 groups
were then analyzed with the Mann–Whitney U test for significantrdiovascular Surgery c Volume 143, Number 1 195
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Mdifferences. A group overview was also prepared for nominal-scaled vari-
ables. To determine differences in these values, the chi-square test of in-
dependence was performed. If the variable was binomial (eg, gender), the
Fisher exact test was applied and the odds ratio with a 95% confidence
interval was calculated. The subgroup analysis was performed with the
Fisher exact test or Mann–Whitney U test according to the scale type
of the corresponding measurement. For all tests in the subgroup analysis,
the Benjamini–Hochberg correction of the significance level was con-
ducted. Kaplan–Meier analysis was performed to estimate the mean
time until the appearance of an infection. To compare the 2 estimates
of the 2 groups, a log-rank test was done. The data were processed and
analyzed while preserving the patient’s anonymity.RESULTS
A total of 720 of 800 (90%) of the screened patients were
included in the study analysis after the end of the 30-day
follow-up period after index surgery. Some 80 of 800 pa-
tients (10%) could not be evaluated, the reasons being revi-
sion surgery because of bleeding (40x), perioperative
mortality not associated with a wound infection (20x),
and non-use of the specified sponge (20x). Some 353 of
720 patients (49%) were assigned to group I (intervention
group; active drug), and 367 of 720 patients (51.0%)
were assigned to group II (control group; placebo). After
the 2 groups were unblinded, it was shown that the interven-
tion and placebo groups differed statistically in a few points
only. There were no significant differences with regard to
the most frequently mentioned risk factors (obesity, diabe-
tes, chronic obstructive pulmonary disease, age, HbA1c, re-
nal impairment, and peripheral arterial obstructive disease).
There were differences in preoperative factors (eg, gender)
(P¼ .041). In the intervention group, 70.5% of the patients
were men versus 77.4% in the placebo group. The differ-
ence in proportions was statistically significant
(P ¼ .041). In addition, an ejection fraction of less than
30% was found in 4.8% of the patients in the intervention
group and in 9.0% of the patients in the placebo group. The
difference of 4.1% was statistically significant (P ¼ .029)
(Table 1).
The incidence of SSWI and DSWI was 11 of 367 patients
(3%) and 13 of 367 patients (3.52%), respectively, in the
control group versus 7 of 353 patients (1.98%) and 2 of
353 patients (0.56%), respectively, in the intervention
group (Table 2).
The probability of developing a DSWI was lower in the
intervention group (66.3%) than in the placebo group.
The non-infection probability in the follow-up period was
significantly higher in the verum group than in the placebo
group (log-rank P ¼ .00529). The numbers needed to treat
relation for all sternal wound infections and DSWI were
1:26 and 1:33, respectively (Figure 3).FIGURE 2. Gentamicin sponge placement and sternal closure. Placement
of the sponge before sternal closure.
ery c January 2012
TABLE 1. Patient characteristics, comorbidities, and procedure-related variables
Active drug Placebo Total P value
Preoperative
Men (%) 249 (70.5) 284 (77.4) 533 (74.0) .041
Age, y 69 (33–85) 69 (29–87) 69 (29–87) .800
BMI 28.1  4.5 28.1  4.3 28.1  4.4 .763
COPD (%) 50 (14.2) 49 (13.4) 99 (13.8) .829
Diabetes mellitus 99 (28.0) 119 (32.4) 218 (30.3) .224
HbA1c (%) 6.25  0.93 6.30  0.96 6.27  0.95 .387
Consuming diseases 11 (3.1) 5 (1.4) 16 (2.2) .133
Myocardial infarction (%) 15 (4.2) 12 (3.3) 27 (3.8) .558
EF<30% 17 (4.8) 33 (9.0) 50 (6.9) .029
Cardiogenic shock (%) 8 (2.3) 5 (1.4) 13 (1.8) .412
Renal impairment (%) 79 (22.4) 91 (24.8) 170 (23.6) .438
Creatinine (mg/dL) 1.06  0.73 1.10  0.60 1.08  0.67 .010
Urea (mg/dL) 40.44  18.95 41.71  22.30 41.09  20.72 .676
GFR 79.6  25.1 76.8  25.1 78.2  25.1 .088
PAOD (%) 41 (11.6) 35 (9.5) 76 (10.6) .397
Osteoporosis (%) 7 (2.0) 5 (1.4) 12 (1.7) .571
Hyperthyroidism (%) 8 (2.3) 5 (1.4) 13 (1.8) .412
Hypothyroidism (%) 22 (6.2) 22 (6.0) 44 (6.1) 1.000
Leucocyte count (n*1000/mL) 7.94  3.61 7.54  2.79 7.74  3.22 0.112
CRP (mg/dL) 1.18  2.87 1.20  2.43 1.19  2.66 0.200
Reoperation 8 (2.3) 25 (6.8) 33 (4.6) .004
Emergency 71 (20.1) 63 (17.2) 134 (18.6) .339
Intraoperative
Type of procedure .197
CABG (þHLM) 186 (52.7) 195 (53.1) 381 (52.9)
OPCAB 30 (8.5) 29 (7.9) 59 (8.2)
Isolated valve surgery 63 (17.8) 86 (23.4) 149 (20.7)
Combination intervention 72 (20.4) 55 (14.7) 126 (17.5)
Other 2 (0.6) 3 (0.8) 5 (0.7)
Procedure-related variables
Operating time, min 252.5  60.0 251.4  59.9 252.0  59.9 .849
Bypass time, min 123.0  45.4 120.4  42.3 121.6  43.8 .455
Clamping time, min 87.9  38.3 87.2  35.4 87.5  36.8 .622
Sternal closure
4 figures of 8 183 (51.8) 209 (56.9) 392 (54.4)
<4 figures of 8 4 (1.1) 2 (0.5) 6 (0.8)
7 conventional 135 (38.2) 127 (34.6) 262 (36.4)
<7 conventional 14 (4.0) 11 (3.0) 25 (3.5)
Other 18 (4.8) 18 (4.9) 35 (4.9)
Postoperative
Ventilation time, min 580.0 565.0 566.5 .377
Transitory psychotic syndrome 75 (21.2) 75 (20.4) 150 (20.8) .854
Thoracic vest 27 (7.6) 19 (5.2) 46 (6.4) .222
Tracheotomy 9 (2.5) 8 (2.2) 17 (2.4) .809
Boldface indicates significant parameters. BMI, Body mass index; COPD, chronic obstructive pulmonary disease; EF, ejection fraction; GFR, glomerular filtration rate;
PAOD, peripheral arterial obstructive disease; CRP, C-reactive protein; CABG, coronary artery bypass grafting; HLM, heart-lung machine; OPCAB, off-pump coronary artery
bypass.
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MDetected bacteria in the 15 patients with DSWI were
coagulase-negative staphylococci (68.4%), gram-negative
bacteria (10.5%), Propionibacterium acnes (10.5%), and
Staphylococcus aureus (5.3%). With only 2 cases of
DSWI in the gentamicin group, a difference between the
2 groups could not be detected.The Journal of Thoracic and CaDISCUSSION
The most serious form of postoperative sternal wound
complication is DSWI. As a disease entity, DSWI occurs
with an incidence of up to 8%1 and is associated with
high morbidity and mortality rates of 14% to 47%.2 This
means that in Germany approximately 2000 patientsrdiovascular Surgery c Volume 143, Number 1 197
TABLE 2. Primary and secondary end points
Active drug Placebo Total P OR (95% CI)
Primary end points
All wound complications 9 (2.54) 24 (6.50) 33 (4.56) .012 0.37 (0.15–0.54)
SSWI 7 (1.98) 11 (2.98) 18 (2.49) .470 0.63 (0.20–1.81)
DSWI 2 (0.56) 13 (3.52) 15 (2.07) .014 0.15 (0.02–0.69)
Active drug Placebo Total P
Secondary end points
Revision 17 (4.8) 11 (3.0) 28 (3.9) .249
Bleeding volume, mL 1411.63  1086.6 1335.7  991.0 1372.9  1038.9 .650
Units of packed red cells 2.5  2.7 2.2  2.8 2.4  2.8 .103
Units of platelet concentrate 0.7  1.2 0.8  1.5 0.8  1.4 .275
Units of fresh-frozen plasma 1.7  3.6 1.5  2.9 1.6  3.3 .840
OR, Odds ratio; CI, confidence interval.
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Mannually develop this serious and potentially life-
threatening complication. Reducing sternal wound infec-
tions lowers mortality and morbidity. It also cuts costs,
because it helps to avoid further surgical and pharmacologic
therapies and shortens hospital stays.21-23 Economic aspects
of mediastinitis were calculated in a matched case-control
study by Graf and colleagues.21 They calculated that me-
dian overall costs of a coronary artery bypass grafting
case were EUR 36,261 per infected patient compared with
EUR 13,356 per control patient without infection
(P< .0001), implying additional costs of approximately
EUR 23.000 per infection. A total of EUR 9154 after reim-
bursement was lost for every case of DSWI during the study
period. Infection control measures for reducing DSWI
therefore seem justified and will become cost-effective.21
The literature contains many articles on the efficacy of
the prophylactic use of a gentamicin-impregnated fleece
in surgery.9,10,12-16 Specifically, the literature contains 3FIGURE 3. Kaplan–Meier plot.
198 The Journal of Thoracic and Cardiovascular Surgstudies on patients undergoing cardiac surgery and the
prophylactic use of a gentamicin sponge: The first study
by Friberg and colleagues14 included 2000 patients exclu-
sively undergoing coronary artery bypass grafting (LOGIP
trial). A total of 967 patients (control group) received rou-
tine intravenous prophylaxis (isoxazolyl penicillin for 48
hours postoperatively) versus 398 patients (intervention
group) who also had 2 gentamicin-collagen sponges
(260 mg) implanted retrosternally (LOGIP trial). The rate
of sternal wound complications was 4.3% in the interven-
tion group versus 9.0% in the control group (P< .001).
This shows a significant beneficial effect of the additional
use of a gentamicin sponge.
The results of the present study support the conclusion of
Friberg and colleagues.14 In terms of gender distribution
and age, the 2 study populations differed only marginally.
However, with a mean body mass index of 28.1  4.4
kg/m2 (LOGIP, 26.4 kg/m2), a diabetic proportion of
30.2% (LOGIP, 18.2), and a chronic obstructive pulmonary
disease proportion of 13.7% (LOGIP, 5.6%), the patients
in our study had a higher overall risk for sternal wound in-
fection. An important difference between the 2 studies con-
cerns the technique of implanting the sponge. In the LOGIP
study, Friberg and colleagues14 used 2 collagen-gentamicin
sponges (260 mg gentamicin), whereas in our study only 1
sponge was implanted, equivalent to 130 mg gentamicin, in
the intervention group. Friberg and colleagues14 placed the
2 sponges between the 2 halves of the sternum, whereas in
this study the sponges were positioned retrosternally.
Which technique is superior and the optimum number of
sponges to be used should be clarified in further studies.
Retrosternal implantation of the sponge in the present study
may have resulted in higher retrosternal gentamicin levels
and consequently lower presternal levels. This could ex-
plain the nonsignificant reduction in SSWIs with a simulta-
neous significant reduction in mediastinitis. Friberg and
colleagues14 observed that the group provided with a genta-
micin sponge had a significantly higher rate of reoperationsery c January 2012
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Mdue to bleeding (4.0% vs 2.3%). Because of our study de-
sign with a placebo group, we are unable to draw any con-
clusions regarding a putatively higher reoperation rate,
although our reoperation rate was comparable at 4.6%.
However, we found no statistical association with the devel-
opment of sternal wound complications. Finally, it should
be noted that the study subjects were not blinded in the
study by Friberg and colleagues,14 which must be seen as
a major limitation.
In the present study, the follow-up contact occurred 1
month after the index operation. There are reports of sternal
wound complications up to 1 year, but more than 90% of
these cases present within 1 month. This is also supported
by the fact that throughout the study period no readmission
for sternal wound infection occurred after 1 month. The de-
sign of the present study meets the criteria of evidence-
based medicine of the highest quality for an individual
study. This is a rarity in surgical research, because such
a study design is usually difficult to realize in the surgical
field. Both study groups showed no significant difference
in the major risk factors. In some points (gender, ejection
fraction< 30%, and reoperation), both groups differed.
An increased risk for a sternal wound infection was not
found in any of the patients in the subgroup analyses in
the present study. Concluding comparability of both groups
is given.
The second study published on this topic was carried out
by Eklund and colleagues13 in 542 patients. They demon-
strated a reduction (without a significant influence) of
SSWI and DSWIs brought about by the use of a gentami-
cin-releasing sponge (4.0% vs 5.9% and 1.1% vs 1.9%, re-
spectively). This unblinded study was also performed
exclusively with 542 patients undergoing elective coronary
surgery, so that neither the statistical power nor the real pic-
ture of daily practice was represented.
The third and most recent study on this topic was pub-
lished by Bennett-Guerrero and colleagues16 in 2010. The
study design chosen was similar to that of the LOGIP study.
However, Bennett-Guerrero and colleagues16 were unable
to confirm the results, and, on the basis of their data, they
concluded that the collagen-gentamicin sponge is ineffec-
tive in preventing sternal wound infections in the context
of cardiac surgery. The study included 1502 patients at 48
US hospitals. The inclusion and exclusion criteria of the
study by Bennett-Guerrero and colleagues16 differed in sev-
eral respects from both the present study and the LOGIP
study. Unlike in the latter 2 studies, the study by Bennett-
Guerrero and colleagues16 enrolled only patients with elec-
tive, non-emergency bypass or valve operations, and these
patients were at increased risk for sternal wound infections.
This higher risk was defined on the basis of diabetes or
a body mass index of more than 30 kg/m2. In our study,
18.6% of the patients underwent urgent or emergency sur-
gery. In the study by Friberg and colleagues,14 this ratio wasThe Journal of Thoracic and Caapproximately 2.3%. In addition, Bennett-Guerrero and
colleagues16 excluded patients with an intraaortic balloon
pump for shock or low-output syndrome. The proportion
of these patients was not recorded in our study, but 1.8%
of the patients had a cardiogenic shock. Other reasons
for exclusion were a serum creatinine level in excess of
3 mg/dL, the need for dialysis because of renal failure, sig-
nificant alcohol abuse, or systemic immunosuppression at
the time of the study. In our study, these parameters were
not regarded as exclusion criteria. The patients in our study
and the LOGIP study by Friberg and colleagues14 were ex-
posed to a broader range of risk factors than the patients in
the study by Bennett-Guerrero and colleagues.16 However,
the overall risk of wound infection was higher in the US
study16 than in our study and the LOGIP study14 because
of the more stringent selection. As did Friberg and
colleagues,14 Bennett-Guerrero and colleagues16 used 2
collagen-gentamicin sponges, each containing 130 mg gen-
tamicin, which were placed between the 2 sternal halves. As
in the LOGIP study, a placebo sponge was not used, in con-
trast with the present study. Another difference among the
studies concerns the number of participating hospitals.
The present study was a single-center study, whereas the
LOGIP study by Friberg and colleagues14 included 2 Swed-
ish hospitals and the US study by Bennett-Guerrero and col-
leagues16 included 48 hospitals in total. It is assumed that
a multicenter study is unsuitable for addressing the question
being investigated. The aim is to evaluate the efficacy of
a single procedure (ie, the use of a gentamicin-collage
sponge) with respect to a complication with a low incidence
and multifactorial genesis. This requires that one needs to
keep all potential influencing factors as constant as possible.
Otherwise, the positive effect of a procedure could be
swamped by the overall influence of a wide range of factors.
In the study by Friberg and colleagues,14 the results were
compromised by the use of different sternal wiring
methods. We now know that the patient presents with
a broad range of risk factors a priori, but the surgical tech-
nique, the type of skin disinfection, the use of 2 pairs of
gloves, the number of people present in the operating
room, and many other factors also have an influence on
wound infections. Thus, it can be speculated that despite
all its positive aspects, a multicenter design is not suitable
for addressing the question concerned in this case.
The US study by Bennett-Guerrero and colleagues16
also clearly showed how greatly surgical procedures differ.
In the gentamicin group, for example, the patient’s hair
was not removed in the operating room in 22.6% of the
cases, and nasal mupirocin was used preoperatively in
48.2% of the patients. Skin disinfection was not standard-
ized (57.5% povidone-iodine, 52.6% alcohol, 47.5%
chlorhexidine-based), and various antibiotics were also ad-
ministered preoperatively (53.5% cefazolin, 23.4% cefur-
oxime, 1.9% ciprofloxacin, 30.5% vancomycin). It canrdiovascular Surgery c Volume 143, Number 1 199
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Mtherefore be speculated that, as in the study by Friberg and
colleagues,14 these different variables may have led to
a distortion of the results. Bennett-Guerrero and col-
leagues16 suspect that dissimilar microbial spectra may
explain the differences in results. In our study,
coagulase-negative staphylococci were the most common
pathogens at 68.4% in the verum group and 50% in the
placebo group. With only 2 cases of DSWI in the gentami-
cin group, a difference between the 2 groups could not be
detected. This microbial spectrum is similar to that in the
Swedish study by Friberg and colleagues,14 in which
coagulase-negative staphylococci formed the largest group
of pathogens. The US study16 showed a heterogeneous mi-
crobial spectrum. A significant difference relates to the
number of S. aureus cases, which accounted for 2.4% (1
case) in the present study, 21.7% in the Swedish study,14
and 37.3% in the US study.16 In our study and the Swed-
ish study,14 no patients had methicillin-resistant S aureus.
By contrast, methicillin-resistant S aureus infection was
identified in 10.2% of the microbial isolates (27.3% of
the S aureus cases) in the US study.16 The extent to which
the dissimilar microbial spectra and possible antibiotic re-
sistance influence the results cannot be clarified.CONCLUSIONS
On the basis of the literature and the results obtained in
this controlled, prospectively randomized, double-blind
study, routine prophylactic retrosternal implantation of an
antibiotic-releasing sponge has a beneficial effect (reduc-
tion in the incidence of sternal wound infections). Because
mediastinitis is a multifactorial complication, an enormous
risk reduction can never be achieved by implementing a sin-
gle measure. Many individual measures must be applied
that in the end will lead to a marked risk reduction. Never-
theless, each building block needs to be evaluated for
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